Expression of GnTIII in a recombinant anti-CD20 CHO production cell line:: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FcγRIII

被引:189
作者
Davies, J [1 ]
Jiang, LY [1 ]
Pan, LZ [1 ]
LaBarre, MJ [1 ]
Anderson, D [1 ]
Reff, M [1 ]
机构
[1] Idec Pharmaceut Corp, San Diego, CA 92191 USA
关键词
production Chinese hamster ovary (CHO) cell; line; glycosylation engineering; GnTIII; immunoglobulin; Fc gamma RIII;
D O I
10.1002/bit.1119.abs
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The gene encoding the rat glycosylation enzyme beta1-4-N-acetylglucosaminyltransferase III (GnTIII) was cloned and coexpressed in a recombinant production Chinese hamster ovary (CHO) cell line expressing a chimeric mouse/human anti-CD20 IgG1 antibody. The new cell lines expressed high levels of antibody and have growth kinetics similar to that of the parent. Relative QPCR showed the cell lines to express varying levels of mRNA. High-performance liquid chromatography (HPLC) analysis showed the enzyme to have added bisecting N-acetylglucosamine (GlcNAc) residues in most (48% to 71%) of the N-linked oligosaccharides isolated from antibody preparations purified from the cell lines. In an ADCC assay the new antibody preparations promoted killing of CD20-positive target cells at approximately 10- to 20-fold lower concentrations than the parent. This activity was blocked using an anti-Fc gamma RIII antibody, supporting the role of Fc gamma RIII binding in this increase. In addition, cell binding assays showed the modified antibody bound better to Fc gamma RIII-expressing cells. The increase in ADCC activity is therefore likely due to an increased affinity of the modified antibody for the Fc gamma RIII receptor. (C) 2001 John Wiley & Sons, Inc.
引用
收藏
页码:288 / 294
页数:7
相关论文
共 16 条
  • [1] BAILEY JE, 1997, METABOLIC ENG N LINK
  • [2] A new Chinese hamster ovary cell line expressing α2,6-sialyltransferase used as universal host for the production of human-like sialylated recombinant glycoproteins
    Bragonzi, A
    Distefano, G
    Buckberry, LD
    Acerbis, G
    Foglieni, C
    Lamotte, D
    Campi, G
    Marc, A
    Soria, MR
    Jenkins, N
    Monaco, L
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2000, 1474 (03): : 273 - 282
  • [3] Cambell C, 1984, J BIOL CHEM, V10, P13370
  • [4] Antibody engineering at the millennium
    Gavilondo, JV
    Larrick, JW
    [J]. BIOTECHNIQUES, 2000, 29 (01) : 128 - +
  • [5] Engineering antibodies for the clinic
    Holliger, P
    Bohlen, H
    [J]. CANCER AND METASTASIS REVIEWS, 1999, 18 (04) : 411 - 419
  • [6] Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions
    Lifely, MR
    Hale, C
    Boyce, S
    Keen, MJ
    Phillips, J
    [J]. GLYCOBIOLOGY, 1995, 5 (08) : 813 - 822
  • [7] Maloney DG, 1997, BLOOD, V90, P2188
  • [8] NARISIMHAN S, 1982, J BIOL CHEM, V257, P10235
  • [9] NEWMAN R, ANTIBODIES, P1
  • [10] IGM AND IGG SECRETION IN HUMAN B-CELL LINES REGULATED BY B-CELL-INDUCING FACTORS (BIF) AND PHORBOL ESTER
    RALPH, P
    SAIKI, O
    MAURER, DH
    WELTE, K
    [J]. IMMUNOLOGY LETTERS, 1983, 7 (01) : 17 - 23